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instruments. The clinical validity and responsiveness of the QLQ-
BM22 was tested by known group comparisons of different 
performance status and response to radiotherapy. 
Results: Two hundred and four patients completed both 
questionnaires at baseline and follow up. On multitrait scaling 
analysis, there was mixed evidence of construct validity, likely 
explained by the format of the questionnaire and population 
characteristics. There was little correlation between most QLQ-
BM22 and QLQ-C15-PAL items, except for the conceptually 
related scales. There were statistically significant differences in 
all QLQ-BM22 scale scores in groups with KPS < 80 versus KPS ≥ 
80 and three out of four QLQ-BM22 scale scores in “responders” 
versus “non-responders” to radiotherapy. In patients who 
responded to radiotherapy, there were statistically significant 
differences in all QLQ-BM22 scale scores between baseline and 
follow up. 
Conclusions: This study further validates the use of the QLQ-
BM22 as a robust and sensitive instrument to assess QOL in 
patients with bone metastases treated with palliative 
radiotherapy. 
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Purpose: Validated tools for evaluating quality of life (QOL) in 
patients with bone metastases include the EORTC QLQ-BM22 and 
QLQ-C15-PAL modules. A statistically significant difference in 
metric scores may not be clinically significant. To aid in their 
interpretation, we performed analyses to determine the minimal 
clinically important differences (MCID) for these QOL 
instruments. 
Methods and Materials: Both anchor-based and distribution-
based methods were used to determine the MCID among patients 
with bone metastases enrolled in a randomized Phase III trial. 
For the anchor-based approach, overall QOL as measured by the 
QLQ-C15-PAL module was used as the anchor and only the 
subscales with moderate or better correlation were used for 
subsequent MCID analysis. In the anchor-based approach, 
patients were classified as improved, stable or deteriorated by 
the change in the overall QOL score from baseline to follow up 
after 42 days. The MCID and confidence interval was then 
calculated for all subscales. In the distribution-based approach, 
the MCID was expressed as a proportion of the standard deviation 
and standard error measurement from the subscale score 
distribution. 
Results: Two hundred and four patients completed both 
questionnaires at baseline and follow up. Only the dyspnea and 
insomnia subscales did not have at least moderate correlation 
with the overall QOL anchor. Using the anchor-based approach, 
10/11 subscales had a statistically significant MCID score for 
improvement and 3/11 subscales had a statistically significant 
MCID score for deterioration. The magnitude of MCID scores was 
higher for improvement in comparison to deterioration. For 
improvement, the anchor-based approach showed good 
agreement with the distribution based approach when using 0.5 
SD as the MCID. However, there was more variability in the 
agreement between these approaches for deterioration. 
Conclusions: We present the MCID scores for the EORTC QLQ-
BM22 and QLQ-C15-PAL QOL instruments. The results of this 
study can guide clinicians in the interpretation of these 
instruments.  
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Purpose: Patients diagnosed with WT in low and middle income 
countries face many incremental challenges compared to those 
diagnosed in high income countries. The objectives of our study 
are: 1) to describe patient outcomes in Ghana; and 2) to identify 
opportunities for improvement.  
Methods and Materials: Methodology Retrospective chart review 
was undertaken supplemented by telephone follow up to 
ascertain disease status and adverse effects. Patients who are 
age ≤ 14 years, diagnosis with WT that is histologically confirmed 
between January 2005 - December 2014, treated with curative 
surgery with or without adjuvant RT at our institution were 
eligible. 
Results: One hundred and one patients were identified. Median 
age was 56 (range 1-168) months and median follow up was 38 
(range 1-86) months. Staging imaging consisted of ultrasound in 
the early years and CT scan since 2012. Fifty-seven patients 
presented with advanced Stage (clinical Stage I 0, II 42, III 25, IV 
31, stage not available 3. All patients were treated with 
neoadjuvant chemotherapy (Vincristine, Actinomycin D ± 
Adriamycin) followed by radical nephrectomy (99), except two 
had upfront surgery. At surgery, advanced stage was found in 73% 
(pathologic Stage I 0, II 29, III 58, IV 14, V 1). Forty-five patients 
were referred for radiotherapy with positive margins (14), 
positive lymph nodes (eight), residual disease (five), peritoneal 
spillage (seven) and unfavourable histology (11). Ten patients did 
not report for RT. Mean interval from surgery to RT was 36.6 
days. 2D technique (APPA fields to the flank or whole abdomen± 
lungs) with 10.8-21.6 Gy in 6-12 fractions was used. Thirty-three 
patients completed RT without interruptions. Acute Grade 2 
toxicities for the RT group included: diarrhea (seven) and 
vomiting in (nine). Late side effects included intestinal 
obstructions (two), chronic renal disease (one) and 
cardiomyopathy (one). Site of first recurrence was within the 
radiation field (five) and distant metastasis (two). Two-year OS 
and DFS were 56% and 44% respectively. Two-year OS for the 
whole group was 31% and 39% respectively. Main reasons for 
interruption were monetary. 
Conclusions: WT patients in Ghana have more advanced 
pathological stage than clinical stage despite neoadjuvant 
chemotherapy. This is attributable to suboptimal pre-operative 
staging. The interval between surgery and RT is long. Quality 
improvement strategies including uniform provision of CT-scan 
for staging and reduction in the interval between surgery and RT 
is achievable in our current practice environment and expected 
to improve outcomes. This is urgently needed. 
